Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1996
|
| gptkbp:approvedBy |
gptkb:United_States
|
| gptkbp:ATCCode |
gptkb:N06DA02
|
| gptkbp:contraindication |
hypersensitivity to donepezil
|
| gptkbp:drugClass |
gptkb:acetylcholinesterase_inhibitor
|
| gptkbp:eliminatedIn |
urine
feces |
| gptkbp:form |
gptkb:tablet
orally disintegrating tablet |
| gptkbp:genericName |
gptkb:donepezil
|
| gptkbp:halfLife |
70 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aricept
|
| gptkbp:indication |
mild to moderate Alzheimer's disease
severe Alzheimer's disease |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
gptkb:Eisai |
| gptkbp:mechanismOfAction |
inhibits acetylcholinesterase
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
Rx only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue insomnia muscle cramps |
| gptkbp:usedFor |
gptkb:Alzheimer's_disease
gptkb:dementia |
| gptkbp:bfsParent |
gptkb:Eisai_Co.,_Ltd.
gptkb:Eisai |
| gptkbp:bfsLayer |
6
|